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ORIGINAL ARTICLE  
ROLE OF ASSESSMENT FOR RETREATMENT WITH 
TRANSARTERIAL CHEMOEMBOLIZATION SCORE IN DECISION OF 
RETREATMENT WITH TRANS-ARTERIAL CHEMO-EMBOLIZATION 
SESSIONS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA 
Anwar Hussain Abbasi, Shahab Abid, Tanveer ul haq, Safia Awan 
Aga khan University Hospital, Karachi-Pakistan 
Background: The objective behind this study was to determine that Assessment for Re-
treatment with Transarterial chemoembolization (ART) score is really applicable in patients 
with hepatocellular carcinoma. Methods: A cross sectional observational study was 
conducted on all patients with hepatocellular carcinoma of intermediate stage and undergone 
≥2 Transarterial chemoembolization. ART score was assessed before and after each session of 
Transarterial chemoembolization. Multi-logistic regression analysis was performed to 
compare the final outcome of patients with ART score of ≥2.5 into groups with two and more 
than two Trans-arterial chemo-embolization sessions. Results: A total of 100 HCC patients 
were recruited for final analysis. Our study participants consisted of total 100 HCC patients. 
Mean Child Pugh score was 6.1±0.95. In our study, most of the study participants (n=63) had 
ART score of less than 1.5 as compared to ART score >2.5 (n=37). A significant proportion 
of patients with ART score of <1.5 prior to second Trans-arterial chemo-embolization had 
better median survival as compared to patients with ART score of >2.5, p-value<0.001. 
Patients with ART score of more than 2.5 did not show any survival benefit after having 3rd 
or 4th Trans-arterial chemo-embolization session, p=0.47. Conclusions: Our study findings 
suggest that those HCC patients who receive multiple sessions of TACE with a low ART 
score have more favourable outcomes with increased survival rate. 
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INTRODUCTION 
Hepatitis C virus infection is the single most 
common cause of end stage sequelae of chronic 
liver disease called hepatocellular carcinoma 
(HCC).1 Hepatocellular carcinoma is now the 5th 
most common cancer among all worldwide.2 
Because of long infective course of HCV infection 
majority of the patients with underlying HCC 
diagnosed at their 5th or 6th decade of life.3 The 
treatment of patients with HCC varies from 
medical therapy to surgical procedures. As per 
Barcelona Clinic Liver Cancer (BCLC) guidelines 
for HCC, various options can be adapted after 
assessing liver function and tumour 
characteristics.4–6 
Mainly population affected with HCC 
present at their advance stage of disease where 
treatment -options become limited and only 
symptomatic treatment can be offered because 
survival of such kind patients not more than 11-20 
months.7–8  Those patients who fall under category 
of intermediate stage HCC and BCLC stage B 
(asymptomatic patients with large or multifocal 
HCC and no extrahepatic extension) are treated 
with Transarterial chemoembolization (TACE).9–11 
On the other hand, TACE can also be used in 
patients who are awaiting for liver transplantation 
as a bridging therapy.12 
Most of the previously conducted studies 
have determined several factors which may affect 
the overall prognosis of TACE such as extent of 
liver dysfunction, tumour size and characteristics, 
levels of alpha-fetoprotein (AFP), child-pugh 
classification, and liver function test. 9–15  
If liver function gets worse after taking 
TACE sessions so these kinds of patients cannot 
take further TACE sessions or any other antitumor 
treatment. 9,11,16 
Sieghart and his colleagues made a 
scoring system named as ART used to predict 
survival of HCC patients after having first TACE 
session.17 This score can only be calculated using 
variables like presence or absence of radiologic 
tumour response, increase in Child score or AST 
(Aspartate transaminase). The methods used to 
calculate ART score is by selecting two separate 
groups of patients who do not share similar 
prognostic value. The ART score cannot be 
accurately calculated in patients who experienced 
more than one sessions of TACE.17 Although, 
majority of HCC patients who are in intermediate 
stage require more than two sessions in a 
sequential manner.11,17,18 That is why prognostic 
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value of repeated TACE session is scientifically 
need to be determine which has not been observed 
in our population and very few international 
literatures are available. So, this study will be 
conducted to determine that ART score is really 
applicable in patients with hepatocellular 
carcinoma at a tertiary care hospital in Pakistan. 
MATERIAL AND METHODS 
This cross-sectional hospital based study was 
conducted at Aga Khan University, Karachi for a 
period of fourteen years (January 2001 to 31st 
December 2014) in all patients admitted in a 
gastroenterology unit for TACE procedure through 
a consecutive sampling technique. 
All diagnosed admitted cases of HCC with 
age more than 18 years of either gender treated 
with more than two sessions of TACE (time 
between the TACE cycles each >90 days) and fall 
under BCLC category of stage A or B along with 
preserved liver functions (Child-Pugh class A or 
B) were enrolled under this study. The diagnosis of 
HCC was made using guideline based diagnostic 
criteria by European Association for the Study of 
the Liver Disease (EASL).5  
Patients who were in child class C or 
BCLC stage C and those patients who received 
TACE prior to orthotopic liver transplantation 
(OLT) or resection, or if patient received TACE 
for HCC recurrence after OLT were excluded from 
the study.  The study approved by the ethical 
review committee of Aga Khan University 
Hospital (ERC #3458-Med-ERC-15) 
We have documented any adverse event that 
occurred within 30 days of any TACE session 
The ART score has three variables (Table-1).  
Table-1: Art score 
ART score Points 
Radiologic tumour response 
Absent 1 
Present 0 
AST increase > 25% 
Present 4 
Absent 0 
Child-Pugh score increase 
1 point 1.5 
≥ 2 points 3 
Absent 0 
 
The ART score is calculated on the basis of sum of 
all three variables. As we have divided the patients 
into two groups based on their ART score as <1.5 
and more than 2.5, the cut off value was set 
accordingly to determine the survival among these 
patients. 
All data entered and analysed by using the 
Statistical package for social science SPSS 
(Release 16.0 and a p-value <0.05 were considered 
as statistically significant. 
Quantitative variables were presented as 
means and SD such as age, AFP, child score, and 
MELD (Model for end stage liver disease) score 
and number (Percentage) for qualitative variables, 
such as gender and aetiology of cirrhosis. In our 
study, the survival of patients was calculated from 
the day of first ART score assessment until the 
patient died or till last visit. Those who lost 
follow-up were excluded from the study. Kaplan 
Meier analysis was performed to measure the in-
hospital outcome in months. Multi-logistic 
regression analysis was performed to observe the 
effect of multiple variables on survival. 
RESULTS 
A total of 790 patients had TACE between January 
2001 to December 2014. Two hundred fifty-six 
patients had ≥2 TACE sessions, 156 patients excluded 
due to missing variables. Total of 100 patients were 
included in the final analysis (Figure-1). 
Out of 100 patients, 51 patients underwent 3 TACE 
sessions and 19 patients underwent 4 TACE sessions. 
Tumour response was present in 14 patients. 
Decompensation after TACE was seen in 15 patients, 
most common decompensation was ascites (14/15 
patients). AST rise was seen in 23 patients after 
TACE. During follow-up period of average 48 months 
(range 20-74 months); overall mortality rate was 
observed out of 100 patients was 80% (n=80). A 
median of 27 months was observed as overall survival 
of patients in our study (95% CI, 11.4–32.7 months). 
The survival was calculated when the date patent was 
enrolled till his/her death. A significant association 
was observed in a univariate analysis among patients 
who underwent 1st TACE with 2nd, 3rd and 4th TACE 
after 27 vs. 25 vs. 12 months, p value 0.01 (Table-3).  
On multivariate analysis, child class and ART score 
had prognostic significance (Table-4) 
Overall, patients with an ART score of 0–
1.5points (n=63) before TACE-2 had a median 
survival of 29 months [95% CI: 26.21-31.78] vs. those 
with some of ≥ 2.5 points (n=37) median survival 
25months [95%CI: 11.10-22.89] p-value 
<0.001(Figure-2). Before TACE-3 and TACE-4 same 
results obtained (Figure-3,4). When a subgroup 
analysis was done in these patients, whether they had 2 
TACE sessions or more than 2 TACE sessions, it was 
observed that there was no survival difference between 
both groups [18 months vs. 21 months, p value 0.47] 
(Figure-5). 
There was no survival difference in patients with HCC 
size <5cm vs. >5cm (Figure-6) or AFP level <200 vs. 
>200 iu/ml (Figure-7). 
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Table-2: Baseline characteristics of study patients (n=100) 
Characteristics Mean+SD/ % Characteristics MEAN +SD/ % 
Age, in years (Mean and SD) 57.53±9.8 MELD score (mean and SD) 9.4±2.3 
Male 82 Tumour size <5cm 62 
Female 18 Tumour size >5 cm 62 
Child score (Mean and SD) 6.1±0.95 BCLC stage 
Child class A 61 
A 71 B 39 
B 29 ∞- Fetoprotein 
Aetiology of cirrhosis <200 65 
HCV 67 ≥200 35 
HBV 17 Tumour response present 14 
NBNC 11 Decompensating after TACE 15 
HBV+HCV 3 AST >25% 23 
BCS 1 Before TACE 2 
ALD 1 Child score 6.5 ± 1.05 
Tumour size Before TACE 3 
<5cm 62 Child score 6.4 ± 0.87 
>5cm 38 Before TACE 4 
  Child score 6.3 ± 1.12 
 
Table-3: Univariate analysis of prognostic factors 
Variable n=100 Median 95% CI p value 
Age 
<65 years 
≥65 
 
64 
36 
 
64 
36 
 
20.06–27.93 
23.92–36.08 
 
0.27 
Aetiology 
Viral 
others 
 
87 
13 
 
27 
21 
 
23.8–30.11 
13.07–28.92 
 
0.65 
∞- Fetoprotein 
<200 
≥200 
 
65 
35 
 
27 
22 
 
21.38–32.61 
17.87–26.12 
 
0.23 
Tumour size 
<5 cm 
>5 cm 
 
62 
38 
 
27 
25 
 
20.66–33.33 
19.44-30.56 
 
0.31 
BCLC stage 
A 
B 
 
61 
39 
 
25 
25 
 
18.81–31.19 
19.34–30.65 
 
0.37 
AST >25% 
No 
Yes 
 
84 
16 
 
27 
14 
 
23.91–30.08 
6.51–21.48 
 
0.19 
Tumour response 
No 
Yes 
 
88 
12 
 
25 
28 
 
20.07–29.92 
24.91–31.08 
 
0.70 
Child score increase 
0 points 
1 points 
≥2 points 
 
66 
27 
7 
 
27 
25 
12 
 
23.20–30.79 
11.40–38.60 
10.71–13.28 
 
 
0.01 
Table-4: Multivariable cox regression of prognostic factors 
Variable Hazard Ratio 95% CI p value 
Child stage 
A 
B 
 
1.0 
3.19 
 
 
1.58–6.44 
 
 
0.001 
ART score 
0-1.5 points 
≥2.5 points 
 
1.0 
2.56 
 
 
1.17–5.59 
 
 
0.01 
AST >25% 
No 
Yes 
 
1.0 
0.37 
 
 
0.16-1.33 
 
 
0.12 
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790 patients has 
TACE b/w Jan 2001 
to December 2014
256 patients had ≥ 
2 TACE sessions
156 excluded due 
to missing 
variables
100 patients 
completed the 
protocol
51 patients had 3 
TACE sessions
19 patients had 4 
TACE sessions
 
Figure-1: Flow diagram 
 
 
 
Figure-2: ART score before TACE 2 
0-1.5 points (n=63): Median survival time: 29months [95% CI: 
26.21-31.78], ≥2.5 points (n=37): Median survival time: 25months 
[95%CI: 11.10–22.89] p value <0.001 
 
 
Figure-3: ART score before TACE 3 
0-1.5 points (n=32): Median survival time: 32months [95% CI: 
27.39–36.60], ≥2.5 points (n=19): Median survival time: 25months 
[95%CI: 16.46–33.53] p value= 0.02 
 
Figure-4: ART score before TACE 4 
0–1.5 points (n=10): Median survival time: 43months [95% CI: 
29.77–56.22], ≥2.5 points (n=9): Median survival time: 30months 
[95% CI: 23.54-36.54] p value= 0.1 
 
Figure-5: Sub-group analysis of patients with 
ART score >2.5 
2 TACE (n=27): Median survival time: 18 months [95% CI: 9.91-
20.08], >2 TACE (n=10): Median survival time: 21 months [95% 
CI: 1–50.44] p value=0.47 
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Figure-6: Survival difference between HCC 
patients with tumour size <5cm vs >5cm 
<5 cm (n=62): Median survival = 27 months [20.66-33.33],n >5cm 
(n=38): Median survival = 25 months [19.44-30.56] p value=0.31 
 
Figure-7: Survival difference between HCC 
patients with AFP <200 vs AFP >200 
<200 (n=65) = Median survival = 27 months [21.38-32.61], >200 
(n=35) = Median survival = 22 months [17.87-26.12] p value=0.23 
DISCUSSION 
HCC is the serious complication of liver 
cirrhosis.1There are various treatment options for 
advance stage HCC including TACE.4–10 In some 
routine treatment procedure patients with HCC 
usually require more than two sessions of TACE to 
achieve desired outcome.11,17 
Significantly favourable survival benefit of 
TACE was observed when comparing the patients 
with ART score of <1.5 with ART score >2.5 before 
going to TACE 2 and TACE 3 (29 months vs. 
25months, p value <0.001 and 32 months vs. 25 
months, p value 0.02, respectively).  
These results are comparable with the results 
of Seighart study, in which patients with favourable 
ART score had better survival as compared to those 
with unfavourable ART score.17,18 
In patients with a dismal ART score (≥2.5 points) 
prior to TACE-2, when we did subgroup analysis, we 
found that there is no survival benefit between 
patients who had only two TACE sessions or more 
than two TACE sessions (survival 18-month vs 21 
months, p value 0.47). If we find ART score (≥2.5 
points), then these patients should not be subjected to 
further TACE sessions and should be offered other 
treatment options like systemic therapy with 
sorafenib etc.19,20  
Few limitations of the study include 
retrospective study design, missing variables of the 
patients with ≥2 TACE sessions so ART score before 
TACE 2 only be calculated in 100 patients. Still 
sample size was adequate to compare the groups with 
high and low ART score. 
CONCLUSION 
Our study findings suggest that those HCC patients 
who receive multiple sessions of TACE with a low 
ART score have more favourable outcomes with 
increased survival rate. 
Acknowledgements: 
We acknowledge the efforts of all the authors in this 
work. 
Conflict of interest:  
There is no conflict of interest related to this article. 
AUTHORS' CONTRIBUTION  
AH: Literature search, conceptualization of study 
design, data collection, write-up. SA: 
Conceptualization of study design, proof reading. 
SA: Data analysis, data interpretation. TUH: Data 
collection, proof reading. 
REFERENCES 
1. Butt AS, Hamid S, Wadalawala AA, Ghufran M, Javed AA, 
Farooq O, et al. Hepatocellular carcinoma in Native South 
Asian Pakistani population; trends, clinico-pathological 
characteristics and differences in viral marker negative and 
viral-hepatocellular carcinoma. BMC Res Notes 2013;6:137. 
2. Butt AS, Abbas Z, Jafri W. Hepatocellular carcinoma in 
Pakistan: where do we stand? Hepat Mon 2012;12(10 
HCC):e6023. 
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 
Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90. 
4. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy 
for staging and treatment: the BCLC update and future 
prospects. Semin Liver Dis 2010;30(1):61–74. 
5. European Association for the Study of the Liver, European 
Organisation for Research and Treatment of Cancer. EASL-
EORTC clinical practice guidelines: management of 
hepatocellular carcinoma. J Hepatol 2012;56(4):908–43. 
6. Bruix J, Sherman M. Management of hepatocellular 
carcinoma: an update. Hepatology 2011;53(3):1020–2. 
7. Peck-Radosavljevic M, Sieghart W, Kolblinger C, Reiter M, 
Schindl M, Ulbrich G, et al. Austrian Joint OGGH-OGIR-
OGHO-ASSO position statement on the use of transarterial 
chemoembolization (TACE) in hepatocellular carcinoma. 
Wien Klin Wochenschr 2011;124(3-4):104–10. 
J Ayub Med Coll Abbottabad 2017;29(3) 
http://www.jamc.ayubmed.edu.pk 383
8. Hucke F, Sieghart W, Schoniger-Hekele M, Peck-
Radosavljevic M, Muller C. Clinical characteristics of 
patients with hepatocellular carcinoma in Austria– is there a 
need for a structured screening program? Wien Klin 
Wochenschr 2011;123(17-18):542–51. 
9. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, 
Bolondi L, et al. Evolving strategies for the management of 
intermediate-stage hepatocellular carcinoma: available 
evidence and expert opinion on the use of transarterial 
chemoembolization. Cancer Treat Rev 2011;37(3):212–20. 
10. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, 
Königsberg R, et al. Advanced-stage hepatocellular 
carcinoma: transarterial chemoembolization versus sorafenib. 
Radiology 2012;263(2):590–9. 
11. Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, 
et al. Response rate and clinical outcome of HCC after first 
and repeated cTACE performed ‘‘on demand’’. J Hepatol 
2012;57(6):1258–67. 
12. Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, 
Fatourou E, Rodriguez-Peralvarez ML, et al. Transarterial 
embolization as neo-adjuvant therapy pretransplantation in 
patients with hepatocellular carcinoma. Liver Int 
2013;33(6):944–9. 
13. Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, 
Riaz A, et al. Alpha-fetoprotein response correlates with 
EASL response and survival in solitary hepatocellular 
carcinoma treated with transarterial therapies: A subgroup 
analysis. J Hepatol 2012;56(5):1112–20. 
14. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro 
V, Piscaglia F, et al. Heterogeneity of patients with 
intermediate (BCLC B) hepatocellular carcinoma: proposal 
for a subclassification to facilitate treatment decisions. Semin 
Liver Dis 2012;32(4):348–59. 
15. Sieghart W, Pinter M, Hucke F, Graziadei I, Schoniger-
Hekele M, Muller C, et al. A single determination of C-
reactive protein at the time of diagnosis predicts long term 
outcome of patients with hepatocellular carcinoma. 
Hepatology 2013;57(6):2224–34. 
16. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Leberre 
MA, et al. Sorafenib or placebo in combination with 
transarterial chemoembolization (TACE) with doxorubicin-
eluting beads (DEBDOX) for intermediate- stage 
hepatocellular carcinoma (HCC): Phase II, randomized, 
double-blind SPACE trial. J Clin Oncol 2012;30 (Suppl 
4):LBA154. 
17. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, 
Mueller C, et al. The ART of decision making: re-treatment 
with TACE in patients with hepatocellular carcinoma. 
Hepatology 2013;57(6):2261–73. 
18. Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, 
Muller C, et al. The ART-strategy: sequential assessment of 
the ART score predicts outcome of patients with 
hepatocellular carcinoma re-treated with TACE. J Hepatol 
2014;60(1):118–26. 
19. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et 
al. Which response criteria best help predict survival of 
patients with hepatocellular carcinoma following 
chemoembolization? A validation study of old and new 
models. Radiology 2012;262(2):708–18. 
20. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, 
Woodward N, Burroughs AK, et al. EASL and mRECIST 
responses are independent prognostic factors for survival in 
hepatocellular cancer patients treated with transarterial 
embolization. J Hepatol 2011;55(6):1309–16.
Received: 22 February, 2017 Revised: 25 March, 2017 Accepted: 16 June, 2017 
Address for Correspondence:  
Anwar Hussain Abbasi, Rawal Institute of Health Sciences, Lehtrar Road, Khanna Dak, Islamabad-Pakistan 
Cell: +92 346 353 6150 
Email: anwar30pk@yahoo.com 
 
 
